Abstract
Lung cancer continues to be the most common cause of cancer-related mortality in the United States and other developed countries. The most common subtype is non-small cell lung cancer (NSCLC). Within NSCLC, we are discovering remarkable molecular heterogeneity. Most current actionable mutations have been identified in patients with adenocarcinoma histology, but now new mutations are being discovered in squamous cell histology patients as well. This molecular heterogeneity provides an opportunity for clinical trials to exploit various candidate oncogene-addicted pathways in NSCLC. This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 226-234 |
| Number of pages | 9 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 10 |
| Issue number | 4 |
| State | Published - Apr 2012 |
| Externally published | Yes |
Fingerprint
Keywords
- Chemotherapy
- Clinical trials
- Molecular markers
- Non-small cell lung cancer
- Targeted therapy
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Metastatic non-small cell lung cancer management : Novel targets and recent clinical advances. / Riess, Jonathan; Wakelee, Heather A.
In: Clinical Advances in Hematology and Oncology, Vol. 10, No. 4, 04.2012, p. 226-234.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metastatic non-small cell lung cancer management
T2 - Novel targets and recent clinical advances
AU - Riess, Jonathan
AU - Wakelee, Heather A.
PY - 2012/4
Y1 - 2012/4
N2 - Lung cancer continues to be the most common cause of cancer-related mortality in the United States and other developed countries. The most common subtype is non-small cell lung cancer (NSCLC). Within NSCLC, we are discovering remarkable molecular heterogeneity. Most current actionable mutations have been identified in patients with adenocarcinoma histology, but now new mutations are being discovered in squamous cell histology patients as well. This molecular heterogeneity provides an opportunity for clinical trials to exploit various candidate oncogene-addicted pathways in NSCLC. This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment.
AB - Lung cancer continues to be the most common cause of cancer-related mortality in the United States and other developed countries. The most common subtype is non-small cell lung cancer (NSCLC). Within NSCLC, we are discovering remarkable molecular heterogeneity. Most current actionable mutations have been identified in patients with adenocarcinoma histology, but now new mutations are being discovered in squamous cell histology patients as well. This molecular heterogeneity provides an opportunity for clinical trials to exploit various candidate oncogene-addicted pathways in NSCLC. This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment.
KW - Chemotherapy
KW - Clinical trials
KW - Molecular markers
KW - Non-small cell lung cancer
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84859642825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859642825&partnerID=8YFLogxK
M3 - Article
C2 - 22706483
AN - SCOPUS:84859642825
VL - 10
SP - 226
EP - 234
JO - Clinical Advances in Hematology and Oncology
JF - Clinical Advances in Hematology and Oncology
SN - 1543-0790
IS - 4
ER -